Oxygenta Pharmaceutical Ltd
Oxygenta Pharmaceutical Ltd (OXYGENTAPH) last reported results for the quarter ended Jun 2026, with sales of ₹37 crore and net profit of ₹-2.1 crore. The stock last traded at ₹46.5, a market capitalisation of ₹172 crore. Over the past 52 weeks the stock has ranged between ₹43 and ₹71.8. Figures are as of 6 Oct 2026 and are not real time.
Oxygenta Pharmaceutical Ltd share price and key metrics
- Current price
- ₹46.5
- Market cap
- ₹172 cr
- Book value
- ₹-11.5
- ROE
- %
- ROCE
- -33.6%
- Dividend yield
- 0.00%
- 52w high / low
- 71.8/43.0
Metrics as of 6 Oct 2026. Not real time.
Track Oxygenta Pharmaceutical Ltd
Cruxal reads every Oxygenta Pharmaceutical Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Oxygenta Pharmaceutical Ltd growth and returns
- 10 Years
- 25%
- 5 Years
- 17%
- 3 Years
- 54%
- TTM
- 21%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -28%
- TTM
- 8%
- 10 Years
- 16%
- 5 Years
- 7%
- 3 Years
- 15%
- 1 Year
- -33%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Oxygenta Pharmaceutical Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹37 cr, up 144.5% from ₹15.13 cr a year earlier. Net profit was ₹-2.1 cr, up 65.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 14.01 | 33.21 | 49.47 | 15.13 | 14.3 | 33.93 | 49.61 | 37 |
| Expenses | 16.18 | 37.57 | 51.15 | 21.96 | 18.87 | 38.01 | 49.49 | 36.45 |
| Operating profit | -2.17 | -4.36 | -1.68 | -6.83 | -4.57 | -4.08 | 0.12 | 0.55 |
| OPM % | -15.49% | -13.13% | -3.40% | -45.14% | -31.96% | -12.02% | 0.24% | 1.49% |
| Other income | 0.75 | 0.49 | -0.22 | 0.16 | -0.06 | 0 | 0.17 | 0.02 |
| Interest | 0.69 | 0.39 | 2.13 | 0.63 | 0.95 | 1.39 | 1.81 | 2.46 |
| Depreciation | 0.66 | 0.71 | -0.23 | 0.85 | 0.86 | 0.86 | -0.24 | 0.62 |
| Profit before tax | -2.77 | -4.97 | -3.8 | -8.15 | -6.44 | -6.33 | -1.28 | -2.51 |
| Tax % | 2.89% | -20.72% | -43.42% | -25.03% | -23.45% | -23.38% | 32.81% | -15.94% |
| Net profit | -2.85 | -3.93 | -2.15 | -6.11 | -4.93 | -4.84 | -1.7 | -2.1 |
| EPS (₹) | -0.80 | -1.06 | -0.58 | -1.65 | -1.33 | -1.31 | -0.46 | -0.57 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Oxygenta Pharmaceutical Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 | 135 |
| Operating profit | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -15 | -8 |
| OPM % | -59% | -31% | -10% | -57% | 7% | 2.4% | -23% | -24% | -9% | -14% | -6% |
| Net profit | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -18 | -14 |
| EPS (₹) | -5.70 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -2.79 | -4.75 | -3.67 |
TTM is the trailing twelve months to the most recent quarter.
Oxygenta Pharmaceutical Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -54 | -63 | -80 |
| Borrowings | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 110 |
| Other liabilities | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 53 |
| Total liabilities | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
| Fixed assets | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 37 | 48 |
| CWIP | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 46 | 72 |
| Total assets | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
As reported by the company. Total assets equal total liabilities by construction.
Oxygenta Pharmaceutical Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | -28 |
| Cash from investing | -1 | -0 | -1 | -0 | -7 | -5 | -10 | -4 | -11 | -14 |
| Cash from financing | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 8 | 43 |
| Net cash flow | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 |
| Free cash flow | -0 | 1 | -8 | -3 | -8 | -7 | -11 | -17 | -8 | -41 |
| CFO / operating profit | -13% | -33% | 396% | 35% | -37% | -106% | 23% | 135% | -29% | 182% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Oxygenta Pharmaceutical Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | — | — | — | — | -1% | -47% | -42% | -33% | -34% |
| Debtor days | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 | 32 |
| Inventory days | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 | 105 |
| Days payable | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 | 174 |
| Cash conversion cycle | -439 | -325 | -73 | -79 | -5 | 16 | -64 | -32 | -18 | -37 |
| Working capital days | -512 | -438 | -164 | -275 | -14 | 8 | -94 | -89 | -184 | -119 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Oxygenta Pharmaceutical Ltd shareholding pattern
Promoters held 56.53% at Jun 2026, down from 57.95% at Jun 2025. DIIs 0.03%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 53.28% | 51.12% | 51.12% | 57.95% | 57.95% | 55.93% | 56.53% | 56.53% |
| DIIs | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Public | 46.69% | 48.84% | 48.84% | 42.02% | 42.01% | 44.05% | 43.44% | 43.43% |
| No. of shareholders | 10,154 | 10,107 | 10,030 | 10,094 | 10,179 | 10,215 | 10,205 | 10,196 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Oxygenta Pharmaceutical Ltd corporate filings
- Oxygenta Pharmaceutical Ltd announces land purchase under SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: The company disclosed a land purchase on October 1, 2026, as per SEBI Regulation 30. No…
Read the full analysis - Closure of trading window for the period ending on 30th September, 2026.Insider Trading / SASTlow impact
- Oxygenta Pharmaceutical Limited Announces Successful Conclusion of 33rd AGM and Approval of Related Party TransactionsAGM/EGMlow impact
Cruxal's analysis: Oxygenta Pharmaceutical Limited has successfully concluded its 33rd Annual General…
Read the full analysis - Oxygenta Pharmaceutical Limited Announces Successful Conclusion of 33rd Annual General Meeting and Approval of Related Party TransactionsAGM/EGMlow impact
Cruxal's analysis: Oxygenta Pharmaceutical Limited has successfully concluded its 33rd Annual General…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.